Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28870268 | 0.83 | — | — | |
| SCHEMBL2866944 | 0.82 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL17317706 | 0.82 | — | — | |
| SCHEMBL19995843 | 0.81 | KDM4E (0.39) | — | |
| SCHEMBL17599560 | 0.78 | POLB (0.33) | POLB | |
| SCHEMBL7974127 | 0.78 | CHRNA7 (0.33) | — | |
| SCHEMBL7974123 | 0.78 | CHRNA7 (0.33) | — | |
| SCHEMBL192685 | 0.78 | — | — | |
| SCHEMBL2159514 | 0.76 | GAA (0.30) | — | |
| SCHEMBL17593010 | 0.76 | GAA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737441-A1 | METHOD FOR PRODUCING ELECTROPHILIC SUBSTITUTED AROMATIC COMPOUND | FUJIFILM Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-20260070931-A1 | METHOD FOR MANUFACTURING ELECTROPHILIC SUBSTITUTED AROMATIC COMPOUND | FUJIFILM CORPORATION (JP) | 2026-03-12 | — | — | US | disclosed |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-12 | — | — | US | disclosed |
| US-20250367173-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC (KR) | 2025-12-04 | — | — | US | disclosed |
| EP-4169925-B1 | PROCESS TO MAKE N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-06-17 | — | — | US | disclosed |
| WO-2025106910-A1 | DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR | FLARE THERAPEUTICS INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-116444495-B | Indolone FLT3 protein degradation agent, preparation method and medical application thereof | 南京中医药大学 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025004786-A1 | METHOD FOR PRODUCING ELECTROPHILIC SUBSTITUTED AROMATIC COMPOUND | 富士フイルム株式会社 | 2025-01-02 | — | — | WO | disclosed |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-24 | — | — | US | disclosed |
| WO-2002016365-A1 | PYRAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MODULATING OR INHIBITING ERAB OR HADH2 ACTIVITY | AGOURON PHARMACEUTICALS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-1173170-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1171122-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6265434-B1 | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. | 2001-07-24 | — | — | US | disclosed |
| WO-2001043740-A1 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6248755-B1 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-06-19 | — | — | US | disclosed |
| EP-1083178-A1 | Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-2000059498-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000059502-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367173-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP1, ENPP3, SMPD1 | POLB 830/4885RIPK1 4628/4885 |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | POLB 1516/4885RIPK1 2160/4885 |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | TPMT, SARS1, NLN | POLB 1900/4885RIPK1 2136/4885 |
| US-20260070931-A1 | METHOD FOR MANUFACTURING ELECTROPHILIC SUBSTITUTED AROMATIC COMPOUND | TRPA1, ALK, MAFK | POLB 1334/4885RIPK1 2874/4885 |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | CCR3, SCN1B, NR3C1 | POLB 1497/4885RIPK1 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.